Episode 211: 211. Pharmacogenomics Testing, PHASER,
Questioning Medicine12 Juli 2023

Episode 211: 211. Pharmacogenomics Testing, PHASER,


(https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf) clearly state there is insufficient evidence to support this activity and testing. This is mainly because of low quality evidence and concern of bias given commercially funded studies.

(https://www.aafp.org/pubs/afp/issues/2023/0100/poems-pharmacogenic-testing-antidepressants.html)

American Psychiatric Association Psychiatry.org - Genetic Testing to Improve Psychiatric Medication Choice

Harvard https://www.health.harvard.edu/blog/gene-testing-to-guide-antidepressant-treatment-has-its-time-arrived-2019100917964

First prime


As I mention in my response email PRIME the primary outcomes per clinnicaltrials.gov were depression remission at 24 weeks, which was not statically significant. And then a use of fewer medications that have a potential gene-drug interaction which from what I can find was a ‘theoretical’ interaction not an actual increase in adverse events. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial | Depressive Disorders | JAMA | JAMA Network




“The PREPARE Study

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113234/#:~:text=Open%2Dlabel%20placebo%20reduced%20minimum,0.02%25%20in%20the%20TAU%20arm. When patients were told they were getting placebo for back pain and it helped their back pain!


The current VA/DoD guidelines clearly state, “For patients who cannot tolerate a statin, we suggest a washout period followed by a rechallenge with the same or a different statin or lower dose, and if that fails, a trial of intermittent (nondaily) dosing”.

https://www.healthquality.va.gov/guidelines/CD/lipids/VADoDDyslipidemiaCPG5087212020.pdf (full disclosure and bias I helped write them)

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects | NEJM was published in the NEJM and then a few weeks later Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials (bmj.com) was published in the BMJ.

Around that same time a publication in JAMA https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2773490 showed that using pharmacogenetic testing resulted in no worse LDL levels (soft endpoint) at one year but also no better


Avsnitt(386)

Episode 368: 379. REPOST mammogram part 1

Episode 368: 379. REPOST mammogram part 1

379. REPORT mammogram part 1

18 Feb 202519min

Episode 367: 378. What is the Best Way To Treat Ductal Carcinoma In Situ

Episode 367: 378. What is the Best Way To Treat Ductal Carcinoma In Situ

https://jamanetwork.com/journals/jama/article-abstract/2828218DCIS is a non-invasive form of breast cancer, meaning the abnormal cells are contained within the milk ducts. For years, the standard trea...

12 Feb 20258min

Episode 366: 377. Does How Long You Have Hypertension Matter?

Episode 366: 377. Does How Long You Have Hypertension Matter?

Association of Duration of Recognized Hypertension and Stroke Risk: The REGARDS Study   (Transition Music - Short and subtle - 2 seconds)Host:  Hypertension is a well-known risk factor for stroke, but...

11 Feb 20257min

Episode 365: 366. Association of dose of inhaled corticosteroids and frequency of adverse events

Episode 365: 366. Association of dose of inhaled corticosteroids and frequency of adverse events

Bloom CI et al. Association of dose of inhaled corticosteroids and frequency of adverse events. Am J Respir Crit Care Med 2025 Jan; 211:54. (https://doi.org/10.1164/rccm.202402-0368OC)  Bloom and coll...

7 Feb 20256min

Episode 364: 364. The safety and efficacy of sodium–glucose cotransporter 2 inhibitor in hospitalized patients

Episode 364: 364. The safety and efficacy of sodium–glucose cotransporter 2 inhibitor in hospitalized patients

Gao FM et al. A systematic review and meta-analysis on the safety and efficacy of sodium–glucose cotransporter 2 inhibitor use in hospitalized patients. Diabetes Care 2024 Dec 1; 47:2275. (https://doi...

4 Feb 20257min

Episode 363: 262. Myocardial injury in patients with hip fracture

Episode 363: 262. Myocardial injury in patients with hip fracture

Is accelerated surgery for hip fracture better for high-risk patients? A recent substudy of the HIP ATTACK trial has shed new light on this topic. The original trial, published in 2020, compared accel...

31 Jan 20255min

Episode 362: 261. What to do with the beta blocker following a Myocardial Infarction

Episode 362: 261. What to do with the beta blocker following a Myocardial Infarction

Today, we're discussing two groundbreaking studies from 2024 that challenge our understanding of β-blocker therapy for secondary prevention after myocardial infarction, or MI.Let's start with a Swedis...

15 Jan 20256min

Episode 361: 260. METHODS MONDAY-- EVENT RATE

Episode 361: 260. METHODS MONDAY-- EVENT RATE

Methods Monday  --- Accuracy of Event Rate and Effect Size Estimation in Major Cardiovascular Trials: A Systematic Review | Cardiology | JAMA Network Open | JAMA Network  During the design of a random...

13 Jan 202510min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
rss-jossan-nina
inga-beiga-morsor
alska-oss
not-fanny-anymore
johannes-hansen-podcast
rss-vuxna-pa-latsas
angestpodden
rss-viktmedicinpodden
sa-in-i-sjalen
sova-med-dan-horning
sexnoveller-deluxe
rss-psykoterapipodden
brottarbroder
rss-aldrig-lagom
rss-basta-livet
rss-sjalsligt-avkladd
giggles-med-wiggles
rss-the-house-podcast-3